The complexity of Alzheimer’s disease (AD) pathogenesis has led to difficulties understanding the disease and, therefore, impacted the development of AD drugs. Immunotherapy is a powerful treatment approach that holds considerable promise for the future. Recently, an anti-β-amyloid monoclonal antibody, aducanumab, was approved by the US Food and Drug Administration (FDA), and the current pipeline of anti- β-amyloid monoclonal antibodies in clinical trials and under the evaluation of regulatory agencies continues to grow. Meanwhile, immunotherapy strategies targeting tau are also under development. As the future unfolds, immunotherapies based on β-amyloid and tau may be promising strategies to reduce the devastating effects of AD.

In this episode, AD specialists Philip Tipton, MD, Mayo Clinic, Jacksonville, FL; Johanne Kaplan, PhD, ProMIS™ Neurosciences, Inc., Cambridge, MA; and Adam Fleisher, MD, MAS, Eli Lilly and Company, Indianapolis, IN, discuss the development of immunotherapeutic strategies for AD targeting β-amyloid and tau.